nach oben

Erschienen in:

06.06.2017 | Original Article

Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group

verfasst von: Shun-ichi Kimura, Hiroyuki Fujita, Hideaki Kato, Nobuhiro Hiramoto, Naoko Hosono, Tsutomu Takahashi, Kazuyuki Shigeno, Naoko Hatsumi, Hitoshi Minamiguchi, Junichi Miyatake, Hiroshi Handa, Nobu Akiyama, Yoshinobu Kanda, Minoru Yoshida, Hitoshi Kiyoi, Yasushi Miyazaki, Tomoki Naoe, Japan Adult Leukemia Study Group (JALSG)

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We performed a nationwide questionnaire-based survey to evaluate the current clinical practices of infectious complications during chemotherapy for acute leukemia in Japan.

Methods

We e-mailed a questionnaire to member institutions of the Japan Adult Leukemia Study Group in September, 2013. The questionnaire consisted of 50 multiple-choice questions covering therapeutic environment, antimicrobial prophylaxis, screening test during neutropenia, empirical therapy for febrile neutropenia, and the use of granulocyte-colony stimulating factor. The results were compared to those of previous surveys conducted in 2001 and 2007, and also to the recommendations described in the guidelines.

Results

Usable responses were received from 141 out of 222 (63.5%) institutions. Chemotherapy for acute myeloid leukemia was performed in protective environment in 90% of the institutions, which increased compared to previous survey (76%). Fluoroquinolones and fluconazole were the most commonly used antimicrobial agents for antibacterial and antifungal prophylaxis, followed by sulfamethoxazole-trimethoprim and itraconazole, respectively. In empirical therapy for febrile neutropenia, monotherapy with β-lactum antibiotics was the first-line therapy in most of the institutions. While empirical antifungal therapy was adopted for persistent fever in more than half of the institutions, preemptive/presumptive therapy was also used in approximately 40% of the institutions. Most of the clinicians were reluctant to use granulocyte-colony stimulating factor routinely in chemotherapy for acute myeloid leukemia.

Conclusions

This study clarified the current clinical practices of infectious complications during chemotherapy for acute leukemia and would provide important information for the development of a suitable guideline in Japan.

Nur mit Berechtigung zugänglich

Japanese Society of Medical Oncology (2012) Practical guideline of febrile neutropenia (FN). Nankodo CO., Ltd., Tokyo

Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrozek K, Swann VL, Minderman H, Block AW, Pixley LA, Christiansen NP, Fay JW, Barcos M, Rustum Y, Herzig GP, Bloomfield CD (1996) Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia Blood 87: 1484–1494

Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C, International Antimicrobial Therapy Group of the European Organization for Research Treatment of C (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy Clin Infect Dis 37: 382–389CrossRef

Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S (2000) A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 45:843–849CrossRef

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad, II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious Diseases Society of America Clin Infect Dis 52: e56–e93

Fujita H, Yoshida M, Miura K, Sano T, Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N, Ohnishi K, Miyawaki S, Naoe T (2009) Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. Int J Hematol 90:191–198CrossRef

Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142:979–995CrossRef

Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group Blood 90:4710–4718

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRef

10.

Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS (1997) 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America Clin Infect Dis 25:551–573CrossRef

11.

Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, et al. (1990) From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever J Infect Dis 161: 381–396CrossRef

12.

Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia Eur J Clin Microbiol Infect Dis 24: 111–118CrossRef

13.

Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study Clin Infect Dis 41: 1242–1250CrossRef

14.

Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S (2012) ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients Bone Marrow Transplant 47: 846–854CrossRef

15.

Masaoka T (2004) Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary Clin Infect Dis 39 Suppl 1: S49-52CrossRef

16.

Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, Schwarer AP, Guy S, Bajel A, Tramontana AR, Spelman T, Slavin MA (2013) Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial Lancet Infect Dis 13: 519–528CrossRef

17.

Oshima K, Kanda Y, Asano-Mori Y, Nishimoto N, Arai S, Nagai S, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M (2007) Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 60:350–355CrossRef

18.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE (2016) Sobel JD (2016) clinical practice guideline for the management of candidiasis. Update by the Infectious Diseases Society of America Clin Infect Dis 62:e1–50CrossRef

19.

Tamura K (2005) Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group Int J Antimicrob Agents 26 Suppl 2: S123-127; discussion S133-140CrossRef

20.

Tamura K, Akiyama N, Kanda Y, Saito M (2015) Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan J Infect Chemother 21: 654–662CrossRef

21.

Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A, Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa S, Ohkuma M, Matsuda T, Nakamura T, Horiuchi A, Kuramoto A, Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H, Takaku F, Gran AMLSG (2002) Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study Br J Haematol 116: 103–112CrossRef

22.

Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R, Naoe T (2011) Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 93:66–73CrossRef

23.

Yoshida M, Ohno R (2004) Antimicrobial prophylaxis in febrile neutropenia Clin Infect Dis 39 Suppl 1: S65-67CrossRef

24.

Yoshida M, Ohno R (2004) Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey Clin Infect Dis 39 Suppl 1: S11-14CrossRef

Titel: Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group
verfasst von: Shun-ichi Kimura
Hiroyuki Fujita
Hideaki Kato
Nobuhiro Hiramoto
Naoko Hosono
Tsutomu Takahashi
Kazuyuki Shigeno
Naoko Hatsumi
Hitoshi Minamiguchi
Junichi Miyatake
Hiroshi Handa
Nobu Akiyama
Yoshinobu Kanda
Minoru Yoshida
Hitoshi Kiyoi
Yasushi Miyazaki
Tomoki Naoe
Japan Adult Leukemia Study Group (JALSG)
Publikationsdatum: 06.06.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-017-3775-8

Springer Medizin

Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group